Amicus Therapeutics Inc [NASDAQ: FOLD] stock went on a downward path that fall over -4.26% on Wednesday, amounting to a one-week price decrease of less than -2.94%.
Over the last 12 months, FOLD stock dropped by -0.62%. The one-year Amicus Therapeutics Inc stock forecast points to a potential upside of 35.77. The average equity rating for FOLD stock is currently 1.31, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $3.33 billion, with 293.59 million shares outstanding and 289.03 million shares in the current float. Compared to the average trading volume of 2.44M shares, FOLD stock reached a trading volume of 6337131 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Amicus Therapeutics Inc [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $17.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.31. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Amicus Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 06, 2024. While these analysts kept the previous recommendation, Wells Fargo raised their target price to Overweight. The new note on the price target was released on May 30, 2024, representing the official price target for Amicus Therapeutics Inc stock. Previously, the target price had yet another raise to $13, while Guggenheim analysts kept a Buy rating on FOLD stock. On December 19, 2023, analysts increased their price target for FOLD shares from 15 to 20.
The Average True Range (ATR) for Amicus Therapeutics Inc is set at 0.47, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 6.75. The Price to Book ratio for the last quarter was 18.77, with the Price to Cash per share for the same quarter was set at 0.84.
FOLD Stock Performance Analysis:
Amicus Therapeutics Inc [FOLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.94. With this latest performance, FOLD shares gained by 11.95% in over the last four-week period, additionally plugging by 10.85% over the last 6 months – not to mention a drop of -0.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 49.38, with the RSI for the last a single of trading hit 46.54, and the three-weeks RSI is set at 50.48 for Amicus Therapeutics Inc [FOLD]. The present Moving Average for the last 50 days of trading for this stock 11.14, while it was recorded at 11.44 for the last single week of trading, and 11.13 for the last 200 days.
Insight into Amicus Therapeutics Inc Fundamentals:
Amicus Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.42 and a Current Ratio set at 3.15.
Amicus Therapeutics Inc [FOLD] Institutonal Ownership Details
There are presently around $106.61%, or 107.41%% of FOLD stock, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 28.59 million shares, which is approximately 9.4382%. PERCEPTIVE ADVISORS LLC, holding 28.06 million shares of the stock with an approximate value of $$278.33 million in FOLD stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $$271.81 million in FOLD stock with ownership which is approximately 9.0458%.
